Valrubicin

From Wikipedia, the free encyclopedia

Template:Short description Template:Cs1 config Template:Short description Page Template:Infobox drug/styles.css has no content.

Page Module:Infobox/styles.css has no content.

Valrubicin
Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found.
Clinical data
AHFS/Drugs.comConsumer Drug Information
MedlinePlusa611021
Routes of
administration		Intravesical
ATC codePage Template:Plainlist/styles.css has no content.
Legal status
Legal statusPage Template:Plainlist/styles.css has no content.
  • In general: ℞ (Prescription only)
Pharmacokinetic data
BioavailabilityNegligible
Protein binding>99%
MetabolismNegligible
ExcretionIn urine
Identifiers
  • 2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-({2,3,6-trideoxy-3-[(trifluoroacetyl)amino]hexopyranosyl}oxy)-1,2,3,4,6,11-hexahydrotetracen-2-yl]ethyl pentanoate
CAS NumberPage Template:Plainlist/styles.css has no content.
PubChem CIDPage Template:Plainlist/styles.css has no content.
PubChem SIDPage Template:Plainlist/styles.css has no content.
IUPHAR/BPSPage Template:Plainlist/styles.css has no content.
DrugBankPage Template:Plainlist/styles.css has no content.
ChemSpiderPage Template:Plainlist/styles.css has no content.
UNIIPage Template:Plainlist/styles.css has no content.
KEGGPage Template:Plainlist/styles.css has no content.
ChEBIPage Template:Plainlist/styles.css has no content.
ChEMBLPage Template:Plainlist/styles.css has no content.
NIAID ChemDBPage Template:Plainlist/styles.css has no content.
PDB ligandPage Template:Plainlist/styles.css has no content.
CompTox Dashboard (EPA)Page Template:Plainlist/styles.css has no content.
Chemical and physical data
FormulaC34H36F3NO13
Molar mass723.651 g·mol−1
3D model (JSmol)Page Template:Plainlist/styles.css has no content.
  • FC(F)(F)C(=O)N[C@@H]5[C@H](O)[C@@H](O[C@@H](O[C@@H]4c3c(O)c2C(=O)c1c(OC)cccc1C(=O)c2c(O)c3C[C@@](O)(C(=O)COC(=O)CCCC)C4)C5)C
  • InChI=1S/C34H36F3NO13/c1-4-5-9-21(40)49-13-20(39)33(47)11-16-24(19(12-33)51-22-10-17(27(41)14(2)50-22)38-32(46)34(35,36)37)31(45)26-25(29(16)43)28(42)15-7-6-8-18(48-3)23(15)30(26)44/h6-8,14,17,19,22,27,41,43,45,47H,4-5,9-13H2,1-3H3,(H,38,46)/t14-,17-,19-,22-,27+,33-/m0/s1 checkY
  • Key:ZOCKGBMQLCSHFP-KQRAQHLDSA-N checkY
Data page
Template:Infobox drug/data page link
Page Template:Nobold/styles.css has no content.  (verify)

Valrubicin (N-trifluoroacetyladriamycin-14-valerate, trade name Valstar) is a chemotherapy drug used to treat bladder cancer.[1] Valrubicin is a semisynthetic analog of the anthracycline doxorubicin, and is administered by infusion directly into the bladder.

It was originally launched as Valstar in the U.S. in 1999 for intravesical therapy of Bacille Calmette-Guérin (BCG)-refractory carcinoma in situ of the urinary bladder in patients in whom cystectomy would be associated with unacceptable morbidity or mortality; however, it was voluntarily withdrawn in 2002 due to manufacturing issues.[2] Valstar was relaunched on September 3, 2009.[3]

Side effects

References

  1. ^ Page Module:Citation/CS1/styles.css has no content.Sharma P, Zargar-Shoshtari K, Sexton WJ (2015). "Valrubicin in refractory non-muscle invasive bladder cancer". Expert Review of Anticancer Therapy. 15 (12): 1379–1387. doi:10.1586/14737140.2015.1115350. PMID 26569509.
  2. ^ "Manufacturing Issues Remain for Indevus' Valstar", U.S. Food and Drug Administration News. The MQN Weekly Bulletin, Jan. 11, 2008
  3. ^ Page Module:Citation/CS1/styles.css has no content."Endo Pharmaceuticals launches VALSTAR for treating recurrent carcinoma in situ bladder tumors" (Press release). 2009-09-03. Retrieved 2009-11-26.

Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found.

Retrieved from "https://cosmopedia.co/index.php?title=Valrubicin&oldid=1266713"